Ken Griffin Cabaletta Bio, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.94 - $8.24 $61,858 - $129,368	15,700 Added 70.72%	37,900 $178,000
Q2 2024 Aug 14, 2024	BUY	$7.22 - $18.82 $37,544 - $97,864	5,200 Added 30.59%	22,200 $166,000
Q1 2024 May 15, 2024	BUY	$16.79 - $25.38 $166,221 - $251,262	9,900 Added 139.44%	17,000 $290,000
Q4 2023 Feb 14, 2024	SELL	$12.21 - $23.36 $26,862 - $51,392	-2,200 Reduced 23.66%	7,100 $161,000
Q3 2023 Nov 14, 2023	BUY	$11.84 - $18.65 $18,944 - $29,839	1,600 Added 20.78%	9,300 $141,000
Q2 2023 Aug 14, 2023	SELL	$7.65 - $13.95 $32,895 - $59,985	-4,300 Reduced 35.83%	7,700 $99,000
Q1 2023 May 15, 2023	SELL	$7.08 - $12.62 $39,648 - $70,672	-5,600 Reduced 31.82%	12,000 $99,000
Q4 2022 Feb 14, 2023	SELL	$0.64 - $9.3 $192 - $2,790	-300 Reduced 1.68%	17,600 $162,000
Q3 2022 Nov 14, 2022	BUY	$0.63 - $2.05 $11,277 - $36,695	17,900 New	17,900 $12,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $54.3M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.